These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Friday, March 14, 2014. They include Alcoa, BP, NetApp, Plug Power and Teva Pharmaceutical.
The chief strategist at Piper Jaffray released his report for March. It details how the second and third quarters typically behave in the mid-term years after a solid first quarter. Here are…
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Friday, March 7, 2014. They include Nokia, Safeway, Sirius XM, Skull Candy and Teva Pharmaceutical.
Most Wall Street firms run model portfolios for their institutional and retail clients. Here are stocks that recently were added to the Piper Jaffray Model Portfolio.
Teva Pharmaceutical Industries is out with its fourth-quarter earnings report, and it looks as though the bad trends may be more and more in the past.
Jon C. Ogg Analysts at at Merrill Lynch see 2014 as a promising year for biotech mergers and acquisitions. A new research report shows which companies they believe will make acquisitions or which will be…
Teva Pharmaceutical resume a deal-making strategy that made it one of the most acquisitive drug companies of the past decade. Could one of these biotech takeover candidates be the next target?
These arethe top analyst upgrades, downgrades and initiations seen from Wall Street research firms for Tuesday, January 7.
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, December 30, 2013.
ThinkstockWith less than a week left in what has been the best year for the S&P 500 since 1997, we have reviewed our top Wall Street firms for their stocks priced under…
ThinkstockPfizer Inc.’s (NYSE: PFE) patent protecting popular erectile dysfunction drug Viagra from generic competition may not expire until April 2020, but Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has acquired rights to launch its…
ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) has moved from a great growth story to one of promise, to one of habitual disappointment. The company’s 2014 guidance is soft yet again. The company…
Jon C. Ogg ThinkstockThe market for pharmaceuticals and biotech drugs just keeps growing. The so-called patent cliff may be affecting Big Pharma companies locally, but a new report from IMS Health shows that the total…
Jon OggThis week marks the beginning of the end for earnings season, and both the Dow Jones Industrial Average and S&P 500 hit new all-time highs last week. Now investors and traders alike…
ThinkstockAfter denying rumors earlier this week that its CEO was considering resigning, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced Wednesday morning that President and Chief Executive Jeremy Levin indeed will depart from…
Trey Thoelcke 